Modulation of excision repair cross complementation group 1 (ercc-1) mrna expression by pharmacological agents in human ovarian carcinoma cells

Reed, 1996, The chemotherapy of ovarian cancer, PPO Update, 10, 1 Reed E, Dabholkar M and Chabner BA, Platinum analogues. In: Cancer Chemotherapy (Eds. Chabner BA and Longo DL), 2nd Edn, pp. 357–378. Lippincott-Raven Publishers, Philadelphia, 1996. Reed E, Platinum analogs. In: Cancer—Principles & Practice of Oncology (Eds. DeVita VT, Hellman S and Rosenberg SA), 4th Edn, pp. 390–400. J. B. Lippincott, Philadelphia, 1993. Young RC, Perez CA and Hoskins WJ, Cancer of the ovary. In: Cancer—Principles & Practice of Oncology (Eds. DeVita VT, Hellman S and Rosenberg SA), 4th Edn, pp. 1245–1252. J. B. Lippincott, Philadelphia, 1993. Lepre, 1990, Interaction of platinum antitumor compounds with DNA, Nucleic Acids Mol Biol, 4, 9, 10.1007/978-3-642-84150-7_2 Parker, 1991, Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced DNA repair of cisplatin–DNA lesions and reduced drug accumulation, J Clin Invest, 87, 773, 10.1172/JCI115080 Dabholkar, 1996, Cisplatin, Cancer Chemother Biol Response Modif, 16, 88 Gosland, 1996, Insights into mechanisms of cisplatin resistance and potential for its clinical reversal, Pharmacotherapy, 16, 16, 10.1002/j.1875-9114.1996.tb02913.x Chen, 1995, Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells, Cell Biol Toxicol, 11, 273, 10.1007/BF00757625 Godwin, 1992, High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis, Proc Natl Acad Sci USA, 89, 3070, 10.1073/pnas.89.7.3070 Hamaguchi, 1993, Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines, Cancer Res, 53, 5225 Masuda, 1988, Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines, Cancer Res, 48, 5713 Lee, 1993, Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3, Carcinogenesis, 14, 2177, 10.1093/carcin/14.10.2177 Sancar, 1994, Mechanisms of DNA excision repair, Science, 266, 1954, 10.1126/science.7801120 Zhen, 1992, Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines, Mol Cell Biol, 12, 3689, 10.1128/MCB.12.9.3689 Jones, 1991, Preferential DNA repair of cisplatinum lesions in active genes in CHO cells, J Biol Chem, 266, 7101, 10.1016/S0021-9258(20)89616-1 Moggs, 1996, Analysis of incision sites produced by human cell extracts and purified proteins during nucleotide excision repair of a 1,3-intrastrand d(GpTpG)–cisplatin adduct, J Biol Chem, 271, 7177, 10.1074/jbc.271.12.7177 Calsou, 1993, DNA excision–repair synthesis is enhanced in a murine leukemia L1210 cell line resistant to cisplatin, Eur J Biochem, 211, 403, 10.1111/j.1432-1033.1993.tb17563.x Aboussekhra, 1996, Nucleotide excision repair in vitro and in normal/abnormal human cells, Cell Pharmacol, 3, 221 Friedberg EC, Walker GC and Siede W, DNA Repair and Mutagenesis, pp. 317–326. ASM Press, Washington, DC, 1995. Dabholkar, 1994, Messenger RNA levels of XPA and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy, J Clin Invest, 94, 703, 10.1172/JCI117388 Taverna, 1994, Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity, Carcinogenesis, 15, 2053, 10.1093/carcin/15.9.2053 Dabholkar, 1992, ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients, J Natl Cancer Inst, 84, 1512, 10.1093/jnci/84.19.1512 Behrens, 1987, Characterization of a cis-diamminedichloroplatinum (II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues, Cancer Res, 47, 414 Saotome, 1989, Cytotoxicity test with simplified crystal violet staining method using microtiter plates and its application to injection drugs, Toxicol In Vitro, 3, 317, 10.1016/0887-2333(89)90039-8 Chomczynski, 1987, Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction, Anal Biochem, 162, 156, 10.1016/0003-2697(87)90021-2 Sambrook J, Fritsch EF and Maniatis T, Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. Manetta, 1994, Cyclosporine enhancement of cisplatin chemotherapy in patients with refractory gynecologic cancer, Cancer, 73, 196, 10.1002/1097-0142(19940101)73:1<196::AID-CNCR2820730134>3.0.CO;2-F Kashani-Sabet, 1990, Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells, J Biol Chem, 265, 11285, 10.1016/S0021-9258(19)38588-6 Rabo, 1996, Different mechanisms are responsible for c-jun mRNA induction by cisplatin and ultraviolet light, Int J Cancer, 65, 821, 10.1002/(SICI)1097-0215(19960315)65:6<821::AID-IJC19>3.0.CO;2-6 Huang, 1991, Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells, Proc Natl Acad Sci USA, 88, 5292, 10.1073/pnas.88.12.5292 Park, 1995, Purification and characterization of the XPF–ERCC1 complex of human DNA repair excision nuclease, J Biol Chem, 270, 22657, 10.1074/jbc.270.39.22657 Biggerstaff, 1993, Co-correction of the ERCC1, ERCC4 and xeroderma pigmentosum group F DNA repair defects in vitro, EMBO J, 12, 3685, 10.1002/j.1460-2075.1993.tb06043.x van Vuuren, 1993, Evidence for a repair enzyme complex involving ERCC1 and complementing activities of ERCC4, ERCC11 and xeroderma pigmentosum group F, EMBO J, 12, 3693, 10.1002/j.1460-2075.1993.tb06044.x van Duin, 1987, Genomic characterization of the human DNA excision repair gene ERCC-1, Nucleic Acids Res, 15, 9195, 10.1093/nar/15.22.9195 Devary, 1991, Rapid and preferential activation of the c-jun gene during the mammalian UV response, Mol Cell Biol, 11, 2804, 10.1128/MCB.11.5.2804 Boyle, 1991, Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA binding activity, Cell, 64, 573, 10.1016/0092-8674(91)90241-P Ofir, 1990, Phosphorylation of the C terminus of Fos protein is required for transcriptional transrepression of the c-fos promoter, Nature, 348, 80, 10.1038/348080a0 Auwerx, 1991, IP-1: A dominant inhibitor of Fos/Jun whose activity is modulated by phosphorylation, Cell, 64, 983, 10.1016/0092-8674(91)90322-P Angel, 1987, Phorbol ester inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor, Cell, 49, 729, 10.1016/0092-8674(87)90611-8 Cooper GM. Oncogenes, 2nd Edn, pp. 260–296. Jones & Bartlett Publishers, Boston, 1995. Scanlon, 1990, Cyclosporin A suppresses cisplatin-induced oncogene expression in human cancer cells, Cancer Treat Rev, 17, 27, 10.1016/0305-7372(90)90013-6 Baldary, 1991, Cyclosporin A blocks calcium-dependent pathways of gene activation, J Biol Chem, 266, 19103, 10.1016/S0021-9258(18)55178-4 Mattila, 1990, The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes, EMBO J, 9, 4425, 10.1002/j.1460-2075.1990.tb07893.x Flanagan, 1991, Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A, Nature, 352, 803, 10.1038/352803a0